MedTrace Logo

Open Clinical Study, Comparing Non-inferiority of Chronic Plaque Psoriasis

NCT01279629 · Status: SUSPENDED · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2011-06-20

No results posted yet for this study

Summary

The purpose of this study is:

To evaluate the efficacy of the drugs under study for treating chronic plaque psoriasis.

\- Population:

50 patients will be selected from both sexes, healthy, between 18 and 65 years with a clinical diagnosis of chronic plaque psoriasis with PASI \<20%, according to the criteria of inclusion and exclusion.

Conditions

Interventions

DRUG

Each patient will receive a sample of the drug test (tazarotene 0.1%) and a control sample of the drug (calcipotriene 0.005%).

Apply the medication once daily, preferably at night, in quantities sufficient to cover only the lesions with a thin layer of the product (an average of 2 mg/cm2).Apply only in lesions of the right hemisphere.

Sponsors & Collaborators

  • Glenmark Farmacêutica Ltda

    lead INDUSTRY

Principal Investigators

  • Sergio Schalka · Medcin Instituto da Pele Ltda

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-02-28

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01279629 on ClinicalTrials.gov